Burk Holdings’s Impact BioMedical IBO Stock Holding History

Burk Holdings’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12	Hold	27	–	–	﹤0.01%	643
2026 Q1	$16	Buy	+27	New	+$13	﹤0.01%	676

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Burk Holdings's IBO Position: Q2 2026 in Review

Burk Holdings held its Impact BioMedical (IBO) position steady in Q2 2026 at 27 shares worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #643.

Burk Holdings first reported a position in IBO in Q1 2026 and has held it in 2 quarters since. The position peaked at $16 in Q1 2026. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

Burk Holdings held 27 shares of Impact BioMedical worth $12 as of Q2 2026.
Burk Holdings left its Impact BioMedical share count unchanged in Q2 2026.
Impact BioMedical made up ﹤0.01% of Burk Holdings's portfolio in Q2 2026, its #643 holding.
Burk Holdings first reported a position in Impact BioMedical in Q1 2026 and has held it in 2 quarters since.
Burk Holdings's Impact BioMedical position peaked at $16 in Q1 2026.
22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Burk Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.